Regulatory approval
Published by the Health Canada. Approved
VERZENIO (abemaciclib) is indicated in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of disease recurrence based on clinicopathological features.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | ER positive, HER2-negative | Invasive Breast Carcinoma | Abemaciclib, Tamoxifen | |
| HC (1) | HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Tamoxifen | |
| HC (1) | ER positive, HER2-negative, PR positive | Invasive Breast Carcinoma | Abemaciclib, Tamoxifen |